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Abstract
BACKGROUND
Cirrhosis is a chronic late stage liver disease associated with hepatitis viruses,
alcoholism, and metabolic disorders, such as Wilson disease (WD). There are no
clear markers or clinical features that define cirrhosis originating from these
disparate origins. We hypothesized that cirrhosis is not one disease and cirrhosis
of different etiology may have differential clinical hepatic features.
AIM
To delineate the liver features between WD-associated cirrhosis and hepatitis B-
associated cirrhosis in the Chinese population.
METHODS
In this observational study, we reviewed the medical data of consecutive
inpatients who had WD-associated cirrhosis or hepatitis B-associated cirrhosis
from January 2010 to August 2018, and excluded patients who had carcinoma,
severe heart or pulmonary diseases, or other liver diseases. According to the
etiology of cirrhosis, patients were divided into two groups: WD-associated
cirrhosis group (60 patients) and hepatitis B-associated cirrhosis group (56
patients). The liver fibrosis degree, liver function indices, and portal hypertension
features of these patients were compared between the two groups.
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RESULTS
No inter-group differences were observed in the diagnostic liver fibrosis markers,
however, clinical features clearly defined the origin of cirrhosis. WD-associated
cirrhosis patients (16-29 years) had lower levels of alanine transaminase,
aspartate transaminase, and bilirubin, lower prothrombin time, lower incidence
of hepatic encephalopathy, and lower portal vein diameter (P < 0.05), compared
to cirrhosis resulting from hepatitis B in older patients (45-62 years). Importantly,
they had decreased risks of progression from Child-Pugh grade A to B (odds
ratio = 0.046, 95% confidence interval: 0.006-0.387, P = 0.005) and of ascites (odds
ratio = 0.08, 95% confidence interval: 0.01-0.48, P = 0.005). Conversely, WD-
associated cirrhosis patients had a higher risk of splenomegaly (odds ratio = 4.15,
95% confidence interval: 1.38-12.45, P = 0.011).
CONCLUSION
WD-associated cirrhosis presents a higher risk of splenomegaly associated with
leukopenia and thrombocytopenia, although revealing milder liver dysfunction
and portal hypertension symptoms, which recommends WD patients to be
monitored for associated complications.
Key words: Chronic hepatitis B; Cirrhosis; Hepatic feature; Liver function; Portal
hypertension; Wilson disease
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: In Asia, especially China, the incidence of Wilson disease (WD) and its
complications is much higher in the younger generation compared to Western societies.
This article looks beyond the well-characterized, generalized definition of cirrhosis. It
addresses an important but simple question: Can the origin of cirrhosis be classified by
clinical features, especially in WD-associated cirrhosis? In this manuscript we define
specific clinical characteristics of WD-associated cirrhosis in young patients which are
very distinct to those of hepatitis-associated cirrhosis in older patients. These important
findings may benefit the clinical diagnosis and ultimate treatment of these younger,
vulnerable WD patients.
Citation: Zhong HJ, Sun HH, Xue LF, McGowan EM, Chen Y. Differential hepatic
features presenting in Wilson disease-associated cirrhosis and hepatitis B-associated
cirrhosis. World J Gastroenterol 2019; 25(3): 378-387
URL: https://www.wjgnet.com/1007-9327/full/v25/i3/378.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i3.378
INTRODUCTION
Wilson disease (WD), also named hepatolenticular degeneration, is an autosomal
recessive disease of copper metabolism caused by mutations in ATP7B, which encodes
a copper transporting ATPase[1,2]. Dysfunction of this ATPase causes copper overload
in the liver, brain, and other organs. Depending on the organs affected, WD has a
wide spectrum of clinical symptoms, including hepatic, neurological, psychiatric, and
ophthalmological  manifestations[2].  As  the  liver  is  the  primary organ for  copper
metabolism and has the highest  expression level  of  copper transporting ATPase,
hepatic changes are usually the earliest and most frequent manifestations in WD
patients[2-4]. Although the prevalence of symptomatic WD is low worldwide (about
1/30000), the frequency of this disease is much higher in the Chinese population
(about  5.87/100000)[2,5].  Cirrhosis  is  a  common  manifestation  in  WD  patients
compared to inpatients with other types of liver diseases[6,7].
Cirrhosis is the 11th most common cause of death globally, accounting for 3.5% of
all-cause mortalities[8]. Therefore, it is important to understand the clinical features of
cirrhosis for prevention and treatment of these manifestations and complications. A
meta-analysis that investigated data from 12 studies estimated that the prevalence of
cirrhosis was 34% in WD patients[9].  Clinical symptoms of WD, especially hepatic
manifestations, often present in the first decade of life, and most occur between the
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ages of 5–35[10]. As a result, WD frequently causes cirrhosis in children and young
adults[9]. In some areas of Iran and India, WD was found to be the primary cause of
cirrhosis in children[11,12]. Generally, cirrhosis is characterized by portal hypertension
and hepatic dysfunction, leading to esophageal varices, splenomegaly, ascites, and
liver injury[13]. However, cirrhosis caused by WD in children and young adults differs
from non-alcoholic fatty liver disease and chronic hepatitis B. As the etiology and
onset age of WD-associated cirrhosis are different from those of other kinds of liver
cirrhosis, WD-associated cirrhosis may involve a different liver injury pathogenesis.
Unfortunately, the hepatic features of cirrhosis in WD patients are less well reported.
Hepatitis B virus (HBV) infection, as the most common chronic viral infection, is
the main cause of cirrhosis worldwide[6,13]. Globally, nearly 257 million people are
living with HBV, and one third of them live in China[14,15]. About 10%–20% of Chinese
patients with chronic hepatitis progress to cirrhosis within 5 years[16], making HBV the
leading cause of cirrhosis in the Chinese population[17]. Therefore, we performed this
study to delineate the liver features between WD-associated cirrhosis and hepatitis B-
associated cirrhosis in the Chinese population.
MATERIALS AND METHODS
Study populations
In  this  observational  study,  we  retrospectively  reviewed  the  medical  data  of
consecutive inpatients who were diagnosed with cirrhosis caused by either WD or
HBV presenting from January 2010 to August 2018 at the First Affiliated Hospital of
Guangdong Pharmaceutical University. The patients were excluded from the study if
they met any of the following criteria: (1) Carcinoma; (2) severe heart or pulmonary
diseases; (3) fatty liver disease, alcoholic liver disease, autoimmune liver disease,
drug-induced liver injury, or hepatic parasitic infection; and (4) incomplete medical
data. Patients who were hospitalized more than once were recorded only once. This
study  was  performed  with  the  approval  of  the  Ethical  Committee  of  the  First
Affiliated Hospital of Guangdong Pharmaceutical University. All patients in the study
were de-identified.
Data collection
The following medical  data were extracted from the subjects’  electronic medical
records:  demographic  characteristics,  history  of  smoking  and  alcohol  drinking,
medical  history  (diabetes,  hypertension,  and  liver  disease),  disease  duration,
manifestations  of  cirrhosis,  imaging  examinations,  and  laboratory  test  results
including alanine transaminase (ALT), aspartate transaminase (AST), serum albumin
(ALB), bilirubin, prothrombin time (PT),  total cholesterol (TC), triglyceride, low-
density lipoprotein (LDL), high-density lipoprotein, white blood cell (WBC) count,
red blood cell (RBC) count, platelet count, procollagen type III N-terminal propeptide
(PIIINP), type IV collagen, laminin, and hyaluronic acid.
In addition, disease duration was calculated based on the onset age of WD or HBV
infection.  Child-Pugh  classification  was  assessed  as  previously  described[18].
Leukopenia was defined as a WBC count < 4.0 × 109/L. Erythropenia was defined as
an RBC count < 4.0 × 1012/L for males or 3.5 × 1012/L for females. Thrombocytopenia
was defined as a platelet count < 100 × 109/L. The indication for splenectomy was
hypersplenism,  characterized  by  splenomegaly,  leukopenia,  erythropenia,  and
thrombocytopenia[19]. Smokers were defined as patients who have smoked at some
stages in their lifetime. Alcohol consumption was defined when patients drank more
than 140g of alcohol per week.
In China, diagnosis of WD is based on the classic criteria: Age of onset; family
history; low serum ceruloplasmin (< 200 mg/L); elevated urinary copper excretion (≥
100 μg/24 h); elevated liver copper (> 250 μg/g dry weight); and elevated urinary
copper excretion after challenge with 2 × 500 mg D-penicillamine (> 1600 μg/24 h)[20].
Chronic  hepatitis  B  was  diagnosed  based  on  the  clinical  manifestations  and
serological and virological examinations[21].
Statistical analysis
The statistical analyses were performed using IBM SPSS statistics software, version 22
(IBM Corp., Armonk, NY, United States). Normally distributed continuous variables
are presented as the mean ± standard deviation. Non-normally distributed continuous
variables are presented as medians and interquartile ranges. Categorical variables are
presented as frequencies and proportions. The statistical significance of the difference
in means between the two groups was tested using the unpaired t-test. The statistical
significance of the difference in medians between the two groups was tested using the
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Mann-Whitney U-test. Categorical variables were tested using the Chi-square test or
Fisher’s exact test. To assess the association between cirrhosis etiology and portal vein
diameter, and the association between cirrhosis etiology and liver fibrosis markers,
multivariable linear regression analysis with a forward stepwise approach was used
to adjust for confounders. To assess whether the risk of ascites, splenomegaly, and
progression from Child-Pugh grade A to B or C differed between WD-associated
cirrhosis patients and hepatitis B-associated cirrhosis patients, logistic regression
analysis with a backward stepwise approach was used. Odds ratios (ORs) and 95%
confidence  intervals  (CIs)  were  estimated.  A  P-value  <  0.05  (two-tailed)  was
considered statistically significant.
RESULTS
Demographics and clinical characteristics
Based on the medical data, 56 inpatients with hepatitis B-associated cirrhosis and 60
with WD-associated cirrhosis were enrolled. The mean age and age range of these
patients recorded in Table 1 clearly demonstrate that WD-associated cirrhosis was
more prevalent in the younger age group, whereas, in general, hepatitis B occurred in
older adults. The percentage of males, disease duration, LDL level, and prevalence of
diabetes, hypertension, alcohol drinking, and smoking were significantly higher in
hepatitis  B-associated cirrhosis patients than in WD-associated cirrhosis patients
(Table  1).  In  patients  with  hepatitis  B-associated cirrhosis,  48.21% (27/56)  were
undergoing treatment with antiviral agents, and 47.06% (24/51) presented with low
HBV DNA (≤ 2000 IU/mL).
Relationship between cirrhotic etiology and liver fibrosis markers
The levels  of  PIIINP,  type  IV collagen,  and hyaluronic  acid  were  lower  in  WD-
associated  cirrhosis  patients  than  in  hepatitis  B-associated  cirrhosis  patients.
However, the level of laminin was higher in WD-associated cirrhosis patients (Table
2).  Despite  presenting with  distinct  clinical  variations,  after  adjustment  for  age,
gender, disease duration, diabetes, hypertension, alcohol drinking, and smoking, the
multivariable linear regression analysis showed no overt differences in any of the four
liver fibrosis markers between the two groups of patients.
Relationship between cirrhotic etiology and liver function indices
The PT and the levels of ALT, AST, and bilirubin, but not the level of ALB, were lower
in WD-associated cirrhosis patients compared with hepatitis B-associated cirrhosis
patients. Additionally, the incidence of hepatic encephalopathy was lower in WD-
associated cirrhosis patients. An important observation showed that the percentage of
patients  with Child-Pugh grades B and C was lower in  WD-associated cirrhosis
patients compared with hepatitis B-associated cirrhosis patients (Table 3). Logistic
regression  analysis  showed  that  patients  with  WD-associated  cirrhosis  had  a
significantly decreased risk of progression from Child-Pugh A to B (OR = 0.046, 95%
CI: 0.006-0.387, P  = 0.005), and a non-significant decreased risk for progression to
Child-Pugh C (OR = 0.164, 95% CI: 0.013-2.063, P = 0.162; Table 4), after adjustment
for  age,  gender,  disease  duration,  diabetes,  hypertension,  alcohol  drinking,  and
smoking, as compared to patients with hepatitis B-associated cirrhosis.
Relationship between cirrhotic etiology and features of portal hypertension
Table 5 shows that the portal vein diameter and incidence of ascites were lower in
WD-associated cirrhosis patients than in hepatitis B-associated cirrhosis. However,
WD-associated cirrhosis patients had a statistical trend toward a higher incidence of
splenomegaly (88.33% vs 75.00%, P = 0.062). Multivariable linear regression analysis
showed  that  WD-associated  cirrhosis  was  associated  with  a  lower  portal  vein
diameter. Moreover, after adjustment for age, gender, disease duration, diabetes,
hypertension, alcohol drinking, smoking, and Child-Pugh classification, the logistic
regression analysis showed that WD-associated cirrhosis patients had a significantly
decreased risk of ascites compared with hepatitis B-associated cirrhosis patients (OR =
0.08, 95%CI: 0.01-0.48, P = 0.005). However, the logistic regression analysis showed
that  WD-associated  cirrhosis  patients  had  a  significantly  increased  risk  of
splenomegaly compared with hepatitis B-associated cirrhosis patients (OR = 4.15,
95%CI: 1.38-12.45, P = 0.011).
Splenomegaly for hematocytopenia
Logistic  regression  analysis  showed  that  splenomegaly  was  associated  with  a
significantly increased risk of leukopenia (OR = 4.41, 95%CI: 1.29-15.12, P = 0.018) and
thrombocytopenia  (OR =  23.08,  95%CI:  2.86-186.11,  P  =  0.003;  Table  6),  but  not
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Table 1  Characteristics of patients with cirrhosis
Wilson disease-associated cirrhosis (n = 60) Hepatitis B-associated cirrhosis (n = 56) P value
Age (yr) 22.00 (16.25-29.75) 52.00 (45.25-62.00) < 0.001
Male gender 27 (45.00) 46 (82.14) < 0.001
Disease duration (years) 3.00 (1.13-7.00) 17.50 (3.25-38.25) < 0.001
Diabetes 1 (1.67) 11 (19.64) 0.001
Hypertension 0 (0) 13 (23.21) < 0.001
Alcohol drinking 0 (0) 12 (21.42) < 0.001
Smoking 2 (3.33) 13 (23.21) 0.001
TC (mmol/L) 4.22 (3.67-4.67) (n = 39) 4.10 (2.71-4.67) (n = 39) 0.327
TG (mmol/L) 0.94 (0.70-1.37) (n = 39) 0.99 (0.65-1.60) (n = 39) 0.853
HDL (mmol/L) 1.40 ± 0.30 (n = 39) 1.16 ± 0.32 (n = 39) 0.786
LDL (mmol/L) 2.17 ± 0.61 (n = 39) 2.28 ± 0.91 (n = 39) 0.014
Data are presented as medians (interquartile ranges) or n (%). HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TC: Total cholesterol; TG:
Triacylglycerol.
erythropenia. Eight patients with WD-associated cirrhosis and seven with hepatitis B-
associated cirrhosis had undergone splenectomy. After splenectomy, 50.00% (4/8) of
WD-associated cirrhosis patients and 28.57% (2/7) of hepatitis B-associated cirrhosis
patients  had a normal WBC count;  62.50% (5/8)  and 28.57% (2/7)  had a normal
platelet count.
DISCUSSION
Liver disease is  the most  common clinical  manifestation of  WD, and cirrhosis  is
frequently  presented  in  these  patients[4].  WD  is  not  a  common  disease,  and  its
pathogenesis  and early onset  of  age are quite  different  from those of  other liver
diseases[2]. The clinical manifestations of WD are diverse[4], and the clinical features of
cirrhosis caused by WD are still unclear. To the best of our knowledge, this is the first
study to  analyze the liver  features  of  WD-associated cirrhosis  and present  clear
distinct features to distinguish WD-associated cirrhosis from hepatitis B-associated
cirrhosis.
In this observational study, compared with patients with hepatitis B-associated
cirrhosis, WD-associated cirrhosis presented in a younger age group, and patients
developed  milder  liver  dysfunction  and  portal  hypertension  manifestations.
Consistent with our finding, a recent study involving 1357 WD patients showed that
39.5%  of  children  and  adolescents  had  cirrhosis  at  diagnosis[22].  As  shown  in  a
previous study, the prognosis of WD patients was excellent if the disease was treated
appropriately[10]. Nonetheless, patients with WD-associated cirrhosis had a higher risk
of  splenomegaly,  which  was  found  to  be  a  risk  factor  for  leukopenia  and
thrombocytopenia. In contrast, due to long periods of immune tolerant phases and
inactive residual phases, liver injury is more likely to occur at more advanced age in
patients with HBV infection[23]. Thus, most patients with HBV infection who progress
to cirrhosis do so after the age of 35 years[23].
The degree of liver fibrosis can be reflected by the levels of serum type III collagen,
type  IV  collagen,  laminin,  and  hyaluronic  acid,  which  are  components  of  the
extracellular matrix during fibrosis[24,25]. Based on the multivariable linear regression
analysis, no significant difference in any of these four markers was found between the
two groups of patients. The results showed that the degree of liver fibrosis might be
similar between WD-associated cirrhosis and hepatitis B-associated cirrhosis patients.
However, these markers do not reflect liver fibrosis directly, and liver biopsy remains
the gold standard method for fibrosis assessment. Thus, new diagnostic markers may
be needed to assess liver damage and prognosis, and discern WD-associated cirrhosis
and hepatitis B-associated cirrhosis treatments.
The liver performs many biochemical functions, such as the synthesis of protein
and clotting factors and the metabolism of bilirubin and ammonia[26].  Thus,  liver
dysfunction, as a feature of cirrhosis, was assessed based on liver injury, synthesis
function, metabolism function, and hepatic functional reserve. Compared with WD-
associated cirrhosis  patients,  more  severe  liver  injury  was  found in  hepatitis  B-
associated cirrhosis patients, based on higher levels of ALT and AST. Moreover, the
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Table 2  Relationship between cirrhotic etiology and liver fibrosis markers
Wilson disease-associated cirrhosis (n = 60) Hepatitis B-associated cirrhosis (n = 53) P value
Type IV collagen (ng/mL) 61.55 (52.18-72.11) 79.48 (63.16-107.56) < 0.001
PIIINP (μg/mL) 79.92(54.68-122.65) 109.16 (70.24-155.30) 0.019
Laminin (ng/mL) 104.09 (92.80-118.21) 96.27 (70.08-116.02) 0.013
Hyaluronic acid (ng/mL) 75.12 (39.27-131.98) 193.16 (74.77-625.90) < 0.001
Data are presented as medians (interquartile ranges). PIIINP: Procollagen type III N-terminal propeptide.
lower ALB level and longer PT in hepatitis B-associated cirrhosis patients indicated a
more  serious  impairment  of  synthesis  function.  It  is  well  known  that  hepatic
encephalopathy,  associated with hyperammonemia,  is  caused by impairment  of
ammonia  detoxification  in  the  liver [27].  Thus,  a  higher  incidence  of  hepatic
encephalopathy and a higher level of bilirubin indicated a more severe impairment of
metabolism function in hepatitis B-associated cirrhosis patients. Additionally, the
Child-Pugh classification system, a comprehensive index, has been the most widely
used model to evaluate liver functional reserve[28]. Our results showed that hepatitis B-
associated cirrhosis was a risk factor for progressing from Child-Pugh grade A to B,
which indicated that hepatitis B-associated cirrhosis could lead to a more serious
impairment of liver functional reserve. Therefore, compared with WD-associated
cirrhosis, hepatitis B-associated cirrhosis seemed to cause a more serious impairment
of liver function.
Portal hypertension, as another feature of cirrhosis, was assessed based on the
portal vein diameter, ascites, and splenomegaly[29,30]. We found that the portal vein
diameter was higher in hepatitis B-associated cirrhosis patients than in WD-associated
cirrhosis patients. However, a previous study involving 167 healthy children from 1
mo to 15 years old showed that portal vein diameter was correlated with age and
height, which means that the wider portal vein diameter in hepatitis B-associated
cirrhosis patients might also result from their more advanced age[31]. Thus, a more
precise method, such as hepatic venous pressure gradient measurement, was needed
to evaluate the portal vein pressure between the two groups of patients[32]. Hepatitis B-
associated cirrhosis patients had a higher risk of ascites, which might result from the
more  serious  portal  hypertension  and  lower  level  of  ALB  caused  by  liver
dysfunction[33].
Splenomegaly is the most common imaging finding of portal hypertension[30]. A
previous study involving 910 cirrhosis patients showed that 50.5% of the patients
presented with splenomegaly[34].  Interestingly, the present study showed that the
incidence of splenomegaly (88.3%) was not only much higher than the incidence in
the previous study, but also much higher than the incidence in hepatitis B-associated
cirrhosis patients (75%). In WD, splenomegaly seems to occur frequently, and it can
even be the earliest clinical manifestation, particularly in children[10]. Consistent with
our finding, previous research estimated that the incidence of splenomegaly is 49.0%
(25/51) in WD patients[35], which is higher than that in chronic hepatitis B patients
(41.7%; 65/156)[36]. After adjustment for potential confounders, there was a 3.15-fold
increased risk of  splenomegaly in WD-associated cirrhosis  patients compared to
hepatitis B-associated cirrhosis patients. There are three possible explanations for
these  results.  First,  non-autoimmune  hemolytic  anemia,  which  can  lead  to
splenomegaly, has been shown to be common and an onset symptom in 10%–15% of
WD patients[37]. Second, high concentration of serum copper might also have toxic
effects on the spleen. Third, with increasing age, the size and function of the spleen
are easily affected[38], and the younger age among WD-associated cirrhosis patients
might also lead to a higher sensitivity of the spleen to all kinds of stimulation.
Additionally,  portal  hypertension could bring about  hypersplenism,  which is
characterized by splenomegaly and pancytopenia due to excessive portal flow[39]. In
this  study,  we  found that  splenomegaly  was  associated  with  increased  risks  of
leukopenia and thrombocytopenia. As risk factors for certain fatal infections and
bleeding  (such  as  spontaneous  bacterial  peritonitis,  urinary  tract  infection,
pneumonia, and esophageal variceal bleeding), leukopenia and thrombocytopenia in
WD-associated  cirrhosis  patients  should  receive  more  attention[40].  Regarding
hypersplenism treatment, a clinical study in China revealed that splenectomy was a
safe  and effective  therapeutic  method for  hypersplenism in WD patients,  and it
demonstrated obvious improvements in WBC and platelet counts in all the patients
after splenectomy[19].  Similarly, in our study, most of the WD-associated cirrhosis
patients with hypersplenism had normal WBC and platelet counts after splenectomy.
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Table 3  Relationship between cirrhotic etiology and liver function indices
Wilson disease-associated cirrhosis (n = 60) Hepatitis B-associated cirrhosis (n = 56) P value
ALT (U/L) 23.00 (17.00-34.75) 33.50 (19.33-81.25) 0.002
AST (U/L) 25.00 (19.00-40.00) 41.50 (27.25-96.50) < 0.001
Albumin (g/L) 40.00 (37.00-43.00) 33.00 (29.25-39.75) < 0.001
PT (s) 14.05 (13.43-14.78) 15.50 (13.93-18.18) 0.003
Bilirubin (μmol/L) 12.40 (8.55-18.38) 21.70 (12.73-41.08) < 0.001
Hepatic encephalopathy 0 (0) 3 (5.36) 0.109
Child-Pugh classification < 0.001
A 54 (90.00) 24 (42.86)
B 4 (6.67) 24 (42.86)
C 2 (3.33) 8 (14.29)
Data are presented as medians (interquartile ranges) or N (%). ALT: Alanine transferase; AST: Aspartate transaminase; PT: Prothrombin time.
The present study had several limitations. First, as gastroscopy was not performed
regularly in the cirrhosis patients,  esophageal varices,  a typical  feature of  portal
hypertension, could not be compared between the two groups of patients. Second,
due to the low economic status of some of the patients and the poor medical services
in some areas of China, the patients often received a delayed diagnosis, which might
have biased the disease  duration assessment.  Third,  some confounders  (such as
medication use and duration from onset to diagnosis of disease), which might have
had an influence on the results, were not taken into consideration. Finally, the study
was a single-center study with a limited sample size. Thus, the results regarding the
comparison  of  hepatic  features  between  WD-associated  cirrhosis  patients  and
hepatitis B-associated cirrhosis patients should be interpreted with caution, and large-
scale, multi-center studies are needed to confirm these conclusions.
In conclusion, in this study, we provide evidence to show that cirrhosis is not one
disease and there is a need for further classification for treatment options. Depending
on  the  origin,  cirrhosis  presents  different  clinical  features.  Our  findings,  in
concurrence with other studies in the literature, show that clinical features occur
earlier in WD patients than in chronic hepatitis B patients. An important observation
made in this study is that progression from Child-Pugh grade A to B or C differed
between  WD-associated  cirrhosis  patients  and  hepatitis  B-associated  cirrhosis
patients. Notably, WD-associated cirrhosis patients had a higher risk of splenomegaly,
which was found to be a risk factor for leukopenia and thrombocytopenia. Based on
these findings, it is highly recommended that young Wilson’s disease patients require
regular monitoring for blood disorders and infections to alleviate further clinical
complications.  Additionally,  splenectomy  might  be  an  effective  therapy  for
hypersplenism in WD-associated cirrhosis patients.
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Table 4  Logistic regression analysis of Child-Pugh classification in patients with Wilson disease-associated cirrhosis vs patients with
hepatitis B-associated cirrhosis
OR 95%CI P value
Child-Pugh classification
A Ref. - -
B 0.046 0.006-0.387 0.005
C 0.164 0.013-2.063 0.162
Data were adjusted for age, gender, disease duration, diabetes, hypertension, alcohol drinking, and smoking. CI: Confidence interval; OR: Odds ratio; Ref:
Reference.
Table 5  Relationship between cirrhotic etiology and features of portal hypertension
Wilson disease-associated cirrhosis (n = 60) Hepatitis B-associated cirrhosis (n = 56) P value
Portal vein diameter (mm) 10.00 (8.00-10.00) 14.00 (12.00-16.00) < 0.001
Ascites 2 (3.33) 24 (42.86) < 0.001
Splenomegaly/splenectomy 53 (88.33) 42 (75.00) 0.062
Data are presented as medians (interquartile ranges) or n (%).
Table 6  Logistic regression analysis of risk of hematocytopenia due to splenomegaly
OR 95%CI P value
Leucopenia 4.41 1.29-15.12 0.018
Erythropenia - - -
Thrombocytopenia 23.08 2.86-186.11 0.003
Data were adjusted for age, gender, disease duration, diabetes, hypertension, alcohol drinking, smoking, and Child-Pugh classification. CI: Confidence
interval; OR: Odds ratio.
ARTICLE HIGHLIGHTS
Research background
Cirrhosis is a chronic late stage liver disease associated with hepatitis viruses, alcoholism, and
metabolic  disorders,  such as  Wilson disease  (WD).  As  the  etiology and onset  age  of  WD-
associated cirrhosis are different from those of other kinds of liver cirrhosis, WD-associated
cirrhosis may involve a distinct liver injury pathogenesis.
Research motivation
We hypothesized that cirrhosis is not one disease and cirrhosis of different etiology may have
differential clinical hepatic features.
Research objectives
To delineate the liver features between WD-associated cirrhosis and hepatitis  B-associated
cirrhosis in the Chinese population.
Research methods
We  performed  a  cross-sectional  study  of  60  WD-associated  cirrhosis  and  56  hepatitis  B-
associated cirrhosis inpatients. We analyzed the liver fibrosis degree, liver function indices, and
portal hypertension features between these two groups.
Research results
No inter-group differences were observed in the diagnostic liver fibrosis markers, however,
clinical features clearly defined the origin of cirrhosis. Cirrhosis presenting in WD patients had
worse liver function, lower incidence of hepatic encephalopathy, and lower portal vein diameter,
compared to cirrhosis resulting from hepatitis B. They had decreased risks of progression from
Child-Pugh grade A to B and of ascites. Conversely, WD-associated cirrhosis patients had a
higher  risk  of  splenomegaly,  which  was  associated  with  a  significantly  increased  risk  of
leukopenia and thrombocytopenia.
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Research conclusions
WD-associated cirrhosis presents a higher risk of splenomegaly associated with leukopenia and
thrombocytopenia,  although  revealing  milder  liver  dysfunction  and  portal  hypertension
symptoms. These findings indicated that cirrhosis is not one disease and further classification for
diagnosis and treatment options, dependent on origin, are needed.
Research perspectives
The higher risk of splenomegaly associated with leucopenia and thrombocytopenia in these
younger,  vulnerable WD patients  with cirrhosis,  suggests  early and regular monitoring of
associated blood disorders and infections to alleviate further clinical complications.
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